Organic Active Ingredients TRIZ Cases

Formula I compounds target the endosomal protein Niemann-Pick C1 to block viral entry, addressing incomplete inhibition from cathepsin inhibitors.

Pyridin-2-one compounds modulate mGluR2 via allosteric binding, achieving subtype selectivity lost by orthosteric ligands.

A topical composition combines L-carnosine and chondroitin sulfate to deliver antioxidant and anti-inflammatory effects directly to affected joints.

Novel piperazine derivative acts as histamine H3 receptor antagonist to treat cognitive impairment in neurological disorders.

An anti-IL-18 antibody neutralizes interleukin-18 cytokines in adult-onset Still's disease treatment.

A method for producing phosphatidylserine using phospholipase A2 esterification and subsequent enzyme inactivation.

An oil-in-water emulsion vehicle reduces local skin irritation while maintaining therapeutic efficacy of low-concentration tazarotene.

A compound binds filamin A to preserve mu opioid receptor Gi/o signaling.

Flow meters and biometric sensors enable precise dosage control while tracking consumption data for secure prescription adherence.

An injectable paliperidone depot uses PLGA and DMSO to form an in situ solid implant.

Modifying C2 substituents prevents PBD dimer aggregation while cleavable linkers ensure targeted intracellular release, minimizing toxicity.

Hydroxylated lapatinib analogs reduce severe liver toxicity and CYP3A4 inhibition while maintaining HER2/neu and EGFR pathway inhibition for cancer treatment.

An elastomeric ocular device constricts episcleral veins to deliver ophthalmic agents directly into the eye.

Buprenorphine treats bowel dysfunction without reversing analgesic efficacy or causing dehydration.

An oral dissolvable film delivers psychedelic compounds through the mucosal membrane.

A dry powder inhaler formulation combines anticholinergic, corticosteroid, and beta-agonist drugs with lactose excipients for triple therapy delivery.

Structural modifications to imidazolinone cores enhance therapeutic efficacy and safety margins by minimizing adverse drug interactions.

Segmentation and composite materials enable targeted delivery of pyrrolobenzodiazepine derivatives to treat DLL3-expressing cancers.

Surfactant mediation stabilizes cannabinoid nanoemulsions, preventing particle aggregation while enhancing water solubility and bioavailability.

A pharmaceutical composition combines polyphenols, flavonoids, spermidine, trehalose, and lentztrehalose to counteract oxidative stress.

Dual absorbents and surfactants improve powder flow to resolve drug content uniformity trade-offs in selective laser sintering.

A shelf-stable supercritical CO2 extracted lipidosterolic extract of Serenoa repens maintains urinary and prostate function.

DiNAC breaks down VWF-platelet clots without triggering hyperfibrinolytic bleeding.

Targeting NLRR-1 with monoclonal antibodies inhibits tumor growth and overcomes resistance mechanisms that limit EGFR inhibitor efficacy.

Segmented bi-layered osmotic device delivers oxybutynin and darifenacin to maintain steady plasma levels while reducing side effects.

Acid degradable solid lipid nanoparticles enable efficient transfection via pH-responsive PEG-lipids.

Targeting the let-7/TGFBR3 axis reduces cardiomyocyte death while improving diagnosis accuracy beyond traditional Troponin biomarkers.

Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives inhibit cathepsin A to treat atherosclerosis and heart failure.

A delayed-release composition of niclosamide enhances solubility and bioavailability through anionic polysaccharide cellulose derivatives.

Segmented amphiphilic pentablock co-polymers maintain clear aqueous stability while delivering both hydrophobic and hydrophilic active agents.

Sialylated oligosaccharides stimulate GLP-1 secretion to control food intake, preventing excessive fat mass accumulation without pharmacological side effects.

Boiling water and ethanol precipitation isolate Cistanche deserticola polysaccharides to regulate the tumor microenvironment and reduce toxic side effects.

Synergistic HDAC6 inhibitor and azacitidine treatment reduces cell viability and increases apoptosis in acute myelogenous leukemia.

RNA expression analysis of specific genes in skin biopsies replaces subjective clinical scoring with standardized molecular data for accurate diagnosis.

Apigenin suppresses miR-155 to restore SHIP-1 expression, reversing the immunosuppressive tumor microenvironment in pancreatic cancer.

A pharmaceutical composition containing branched-chain amino acids and carboxylic acids restores liver metabolic function.

Modular structural optimization enhances chemical stability and selectivity against PDE3 and PDE10 for neurological disorders.

Asymmetric cyclodextrin dimers selectively bind and remove 7-ketocholesterol without depleting essential cholesterol.

Replaces invasive surgery with a topical composition achieving complete remission without scarring.

DNA aptamers with G-quadruplex structures bind specifically to azole-class antifungal drugs for sensitive biosensor detection.

Mass spectrometry quantifies nucleoside analogue incorporation into genomic DNA using stable heavy-isotope internal standards.

LNA-modified antisense oligonucleotides achieve potent FoxP3 knockdown at low doses, avoiding toxicity from high-dose administration.

A nutritional composition incorporating exogenous vitamin K2 to modulate inflammation and preserve muscle protein synthesis.

Controlled release multiparticulate dosage forms combine sustained and immediate release beads to deliver deutetrabenazine.

Alginate sulfate interferes with pathogenic gene expression to address limited efficacy of existing vaccines and safety concerns.

Pyrimidine derivatives modulate LRRK2 kinase activity through targeted molecular structures.

Selective inhibition of PI3K-delta and gamma isoforms minimizes off-target effects on PI3K-beta.

A non-extractable oral solid dosage form uses a tacky amorphous polymer matrix to entrap active ingredients.

Formula I compounds inhibit PTPN2 and PTPN1 enzymes, addressing the lack of effective targeted inhibitors in current cancer treatments.